TNNI3 Antibody

Code CSB-PA050278
Size US$100
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
TNNI3
Alternative Names
cardiac muscle antibody; Cardiac troponin I antibody; cardiomyopathy; dilated 2A (autosomal recessive) antibody; Cardiomyopathy; familial hypertrophic; 7; included antibody; CMD1FF antibody; CMD2A antibody; CMH7 antibody; cTnI antibody; Familial hypertrophic cardiomyopathy 7 antibody; MGC116817 antibody; RCM1 antibody; Tn1 antibody; Tni antibody; TNN I3 antibody; TNNC 1 antibody; TNNC1 antibody; TNNI3 antibody; TNNI3_HUMAN antibody; Troponin I antibody; Troponin I cardiac antibody; Troponin I cardiac muscle antibody; Troponin I cardiac muscle isoform antibody; Troponin I type 3 cardiac antibody; troponin I; cardiac 3 antibody; TroponinI antibody; Ttroponin I type 3 (cardiac) antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Synthesized peptide derived from Human Troponin I-C around the non-phosphorylation site of T142.
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
WB, IHC, IF, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IHC 1:100-1:300
IF 1:200-1:1000
ELISA 1:40000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
Gene References into Functions
  1. Data show that the incident atrial fibrillation (AF) occurrence group had similar baseline troponin I (TnI) levels, but higher troponin T (TnT) levels [Review and Meta-Analysis]. PMID: 29631448
  2. Studies indicate that in patients with end-stage renal disease (ESRD), elevation of cardiac-specific troponin T (cTnT) was more frequent than elevation of troponin I (cTnI) [Review]. PMID: 28545334
  3. the frequency of h-FABP positivity among acute myocardial infarction patients was higher than that of hs-TnI, which would have missed six of them; however, hs-TnI area under curve was superior to that of h-FABP. PMID: 28650717
  4. Reversible Covalent Reaction of Levosimendan with Cardiac Troponin C in Vitro and in Situ. PMID: 29558109
  5. The QT interval has a strong positive linear correlation with cardiac troponin-I levels in Non-ST-elevation myocardial infarction. PMID: 28366473
  6. Apelin-12 influences troponin I levels in the acute phase of STEMI, whereas during the non-acute phase, low apelin levels were associated with a high rate of MACE. PMID: 28728608
  7. In clinical stable patients without known cardiovascular disease, a thorough chest-pain history in combination with hs-TnI testing can identify a significant low-risk group. PMID: 28031149
  8. Study showed that in patients who underwent liver transplantation elevation of preoperative high-sensitivity cardiac troponin I level was associated with 1-year mortality and 30-day mortality. PMID: 28542299
  9. Serial measurement of troponin I revealed a persistent elevation in patients with diabetes mellitus type 2. PMID: 28246236
  10. Plasma troponin C1 (cTnI) is biomarker of choice for diagnosing acute myocardial infarction (AMI) because of its high specificity as biomarker for damage to myocardial tissue. Data suggest the "best cut-off" for plasma cTnI is 0.014 micrograms/L in AMI. These studies were conducted in emergency department of a university hospital in Italy using point-of-care testing in patients presenting with chest pain, ages 18-101. PMID: 28377153
  11. NT-proBNP and hs-cTnI levels were higher in systemic sclerosis patients than controls. Both NT-proBNP and hs-cTnI were associated with the presence of echocardiographic abnormalities. PMID: 27601074
  12. value of cTnI level assessed 24 hours post-surgery was a reliable predictor of death following liver transplantation with optimal cut-off value of 0.215 ng/mL. The surgery time was the most important predictor of cTnI elevation. PMID: 28455997
  13. cTnI levels are common in Fabry disease patients, reflecting cardiac involvement. PMID: 27322070
  14. Report novel troponin I rule-out value below the upper reference limit for acute myocardial infarction. PMID: 27067356
  15. cTnI determined in hemodynamically stable patients with suspected AMI and wide QRS complex using optimized diagnostic thresholds improves rule-in and rule-out with respect to presence of a significant obstructive CAD PMID: 27148734
  16. 83 preterm infants with Bronchopulmonary dysplasia born <28-wk gestation and still inpatients at 36-wk corrected age received an echocardiogram and blood tests of B-type natriuretic peptide (BNP), troponin I, and YKL-40. PMID: 27760764
  17. Serum cardiac troponin I was increased in septic patients with myocardial depression compared to those without myocardial depression. PMID: 27238916
  18. Elevated BNP and hs-cTnI after kidney transplantation identify candidates for targeted risk reduction. PMID: 26910333
  19. These perturbed biophysical and biochemical myofilament properties are likely to significantly contribute to the diastolic cardiac pump dysfunction that is seen in patients suffering from a restrictive cardiomyopathy that is associated with the cTnI R145W mutation. PMID: 27557662
  20. epigenetic modification caused cTnI expression decrease is one of the possible causes that result in a reduced cTnI level and diastolic dysfunction in older mouse hearts PMID: 27184165
  21. Among hospitalized patients with cardiac troponin I values above 30 ng/L, the majority will have myocardial injury. Cardiac nonischemic conditions are associated with very high troponin concentrations, but the outcome is rather good. In contrast, myocardial injury related to noncardiac or multiple conditions carries a very poor long-term prognosis. PMID: 26763756
  22. troponin I carboxy terminal mobile domain and linker sequence has a role in regulating cardiac contraction PMID: 26971468
  23. the last 5 C-terminal residues of cTnI influence the binding of cTnI with cTnC and cTnT and affect the Ca(2+) dependence of filament sliding PMID: 26919894
  24. Study found that N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I are independently associated with incident dementia and NT-proBNP with incident Alzheimer's disease PMID: 28039523
  25. The clones were selected using microtiter plate coated with human cardiac troponin I (hcTnI). Product of hybridoma cells that bind with high affinity to human cardiac troponin I were selected PMID: 27556913
  26. Sex, age, and systolic blood pressure belong to the strongest determinants of hs-cTnI in healthy adults. PMID: 27535138
  27. This review summarizes the recent proteomic data on aminoacid sequences of cTnT and cTnI in various species, as well as selected analytical characteristics of human cardiac troponin high-sensitivity assays PMID: 26876101
  28. In stable coronary artery disease patients successfully treated with PCI, pre-procedural cTnI levels, in the upper limits of the normal range, are associated with hard cardiac endpoints. PMID: 25405803
  29. Calcium channel blockers and adrenergic beta antagonists reduced hs-TnI levels significantly both at rest and during exercise in atrial fibrillation patients/. PMID: 27142292
  30. Compromised interactions of K206I with actin and hcTnC may lead to impaired relaxation and HCM. PMID: 26553696
  31. hsTnI at the time of presentation followed by early advanced coronary CTA assessment improves the risk stratification and diagnostic accuracy for acute coronary syndromes. PMID: 26476506
  32. These findings showed that a double heterozygous mutation in the TNNI3 gene is involved in the pathogenesis of hypertrophic cardiomyopathy via haploinsufficiency. PMID: 26506446
  33. The incidence of adverse cardiovascular events was significantly higher in patients with troponin elevation after carotid endarterectomy, which was mainly attributable to silent non-ST segment elevation MIs that occurred in the early post-operative phase. PMID: 26553374
  34. Four novel missense variants were identified in TNNI3. PMID: 26169204
  35. Letter/Case Report: acute decompensated heart failure with troponin I elevation in hereditary hemochromatosis. PMID: 25916738
  36. In this pilot study, the addition of CACS to hsTnI improves the identification of low-risk subjects in whom CTA might be avoided. PMID: 26049777
  37. Exclusion of acute myocardial infarction 2h after presentation in emergency patients with possible acute coronary syndrome can be achieved using hs-cTnT or hs-cTnI assays. PMID: 24316100
  38. Hybrid coronary revascularization is associated with lower postoperative cTn release, compared with off-pump coronary artery bypass surgery. PMID: 25217621
  39. Carotid endarterectomy is followed by a high incidence of asymptomatic cTnI increase that is associated with late cardiac events. PMID: 25601178
  40. mutations underlying restrictive cardiomyopathy all marked by right-sided cardiac manifestations in South African patients PMID: 25940119
  41. Circulating levels of sensitive cTnI and NT-proBNP are related to LV function and infarct size in patients with stable CAD after revascularization. PMID: 25788439
  42. Serum TnI detected significant myocardial necrosis in a majority of patients with chronic HF due to LVSD and when measured serially, provided independent risk information for poor CV outcomes and deleterious LV remodeling. PMID: 25777344
  43. The elevation of Tn I after PCI in patients with normal initial level is more significant predictor of early (30-day) mortality compared to later (within 12 months) mortality. PMID: 25617100
  44. AF patients both without and with CAD showed similar cTnI concentrations at admission. A second validation of cTnI is mandatory for all patients. PMID: 25653186
  45. cardiac troponin T or troponin I compared to creatine kinase in patients with revascularized acute myocardial infarction PMID: 25381953
  46. Even a single elevated Troponin I value increased the risk of myocardial infarction. PMID: 25195101
  47. Abbott high-sensitivity cardiac-TnI levels in a total of 3314 Korean patients with chest pain, were determined. PMID: 25887868
  48. Absolute delta performed significantly better than relative delta at all time intervals to measure changes in troponin I for early diagnosis of myocardial infarction. PMID: 25261587
  49. The high accordance with LGE, reflecting cardiac dysfunction, suggests that cTNI-elevation can be a useful laboratory parameter for assessing myocardial damage in FD. PMID: 24626231
  50. Using an overall 99th percentile for cTnI does not appear to increase the prevalence of myocardial injury or lead to further hospital admissions from the emergency department. PMID: 26185217

Show More

Hide All

Involvement in disease
Cardiomyopathy, familial hypertrophic 7 (CMH7); Cardiomyopathy, familial restrictive 1 (RCM1); Cardiomyopathy, dilated 2A (CMD2A); Cardiomyopathy, dilated 1FF (CMD1FF)
Protein Families
Troponin I family
Database Links

HGNC: 11947

OMIM: 115210

KEGG: hsa:7137

STRING: 9606.ENSP00000341838

UniGene: Hs.709179

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*